Modernizing the diagnostic and decision-making pathway for prostate cancer

Area of Science:

• Urology
• Radiology
• Oncology

Background:

• Prostate-specific antigen (PSA) testing significantly increased prostate cancer detection but not mortality reduction.
• Widespread PSA screening leads to overdiagnosis and overtreatment of indolent prostate cancer.
• Current diagnostic pathways require improvement to avoid negative impacts on patient quality of life.

Discussion:

• Multiparametric MRI (mp-MRI) enhances PSA test accuracy and overcomes limitations of random biopsy sampling.
• mp-MRI identifies aggressive cancer foci suitable for targeted treatment.
• Fusion of mp-MRI with ultrasound enables lesion-targeted biopsies.

Key Insights:

• Targeted biopsies guided by mp-MRI focus on clinically significant prostate cancer.
• This strategy reduces overdiagnosis and overtreatment, improving patient quality of life.
• mp-MRI and targeted biopsies support active surveillance and focal therapy.

Outlook:

• Standardization of mp-MRI acquisition and interpretation is crucial for widespread adoption.
• Further validation of targeted biopsy strategies is needed before replacing random sampling.
• Ongoing research and multidisciplinary efforts aim to establish imaging-guided biopsies as the new standard of care.